Table 1.
Clinical characteristics of and biochemical variables in the patient cohort.
| Patients, number (n) 60 | |
|---|---|
| Male sex, n, (%) | 40 (67) |
| Age, years median (range) | 57.5 (23–91) |
| Current or ex-smoker, n (%) | 34 (57) |
| Cardiovascular disease, n (%) | 34 (57) |
| Chronic pulmonary disease, n (%) | 15 (25) |
| Acute renal failure, n (%) | 10 (17) |
| Chronic renal failure, n (%) | 7 (12) |
| Renal replacement therapy, n (%) | 3 (5) |
| Diabetes, n (%) | 15 (25) |
| Body mass index (kg/m2), median (range) | 30 (22–45) |
| Immunocompromised# at inclusion, n (%) | 8 (13) |
| Symptom duration, days median (range) | 10 (2–30) |
| Length of hospital stay, days median (range) | 7 (2–54) |
| Deceased, n (%) | 2 (3) |
| COVID-19 severity: | |
| Mild, n (%) | 6 (10) |
| Moderate | 25 (42) |
| Severe, n (%) | 21 (35) |
| Critical, n (%) | 8 (13) |
| Mechanical ventilation, n (%) | 4 (7) |
| Mechanical ventilation, days median (range) | 13.5 (2–21) |
| Intensive care, n (%) | 8 (13) |
| Stay at intensive care unit, days median (range) | 9 (1–24) |
| Anticoagulants, n (%) | 60 (100) |
| Remdesivir, n (%) | 23 (38) |
| Corticosteroid therapy, n (%) | 38 (63) |
| Biochemical variables at inclusion: | |
| Haemoglobin g/L, median (range) | 127 (87–171) |
| White blood cell count (x 109/L), median (range) | 6.7 (0.4–47) |
| Platelet count (x 109/L), median (range) | 240 (20–668) |
| Neutrophil count (x 109/L), median (range) | 5.0 (0.1–17.5) |
| Lymphocyte count (x 109/L), median (range) | 1.0 (0.1–33) |
| NLR, median (range) | 4.9 (0.2–88) |
| NMR, median (range) | 13.1 (4.0–180) |
| C-reactive protein (mg/L), median (range) | 62.5 (6–477) |
| Sodium (mmol/L), median (range) | 138 (128–144) |
| Potassium (mmol/L), median (range) | 3.9 (3.2–4.8) |
| Plasma creatinine (μmol/L), median (range) | 69.5 (36–1224) |
| eGFR MDRD (mL/min/1.73m2), median (range) | 69 (4–>90) |
| Lactate dehydrogenase (μkat/L), median (range) | 6.5 (3.2–16) |
# Disease and/or current medical treatment that suppress the immune system, such as haematological or other malignancy, rheumatic disease, and organ transplantation. HFNOT, high flow nasal oxygen therapy; eGFR, estimated glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; NMR, neutrophil-to-lymphocyte ratio. Disease severity was classified according to the National Institute of Health and approximated with respect to maximum oxygen need as mild (pandemic department, no oxygen supplementation), moderate (pandemic department, oxygen supplementation <5L/min), severe (pandemic department or intermediate care unit, oxygen need ≥5L/min supplemented by high-flow nasal oxygen therapy or continuous positive airway pressure therapy) and critical illness (intensive care unit, with or without mechanical ventilation).